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us to advocate clearly for either one or the other surgical
approach at the current time. Pending the development of
more effective multimodality therapy, careful patient selec-
tion for both EPP and P/D on the basis of the cardiopulmo-
nary function, extent of the tumor, and ability to resect all
gross disease remains key to offering patients good treatment
with acceptable risk. Given the limitations that EPP and P/D
impose on the options for adjuvant therapy, we believe that
the choice of surgical procedure must also take into account
for each patient a multidisciplinary decision about the use of
nonsurgical therapies. Finally, our results emphasize the need
for additional well-designed prospective trials that address
the impact of these surgical procedures on outcome and pat-
terns of relapse within the context of multimodality therapy.
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Discussion
Dr D. Sugarbaker (Boston, Mass). It now seems that aggressive
surgical resection by EPP or P/D has an established role for treating
MPM particularly, and I think exclusively, in patients whose disease
is confined to the hemithorax. As you pointed out, there continues to
be controversy and, I would suggest, confusion over whether EPP or
P/D is a better operation. I have argued previously that achieving
a macroscopic complete resection (MCR) is the goal, as you have
suggested here as well, of mesothelioma surgery, whichever proce-
dure is used.
When comparing outcome for these procedures, one needs to be
mindful of the other prognostic factors that you have reviewed here
that affect survival. The principal factor, of course, is cell type, with
pure epithelial tumors behaving better in all published series than the
mixed or sarcomatous lesions. In addition, N2 node status, as re-
ported by our group at the Brigham, and disease bulk, as reported
by Harvey Pass, are significant prognostic factors. Particularly
when one considers bulk disease, as you have suggested, EPP is
many, many times the only operation where an R0 or MCR can be
achieved. I would therefore urge cautious interpretation of survival
comparisons between patients receiving P/D or EPP who do not at
least demonstrate a balance in these important prognostic factors.
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In addition, I think your presentation highlights what I have sug-
gested, that non-epithelial MPM represents a distinct clinical entity
that should be examined and reported separately from epithelial
MPM. These subgroups of patients are different, their clinical course
is dramatically different, and it may be that their therapies eventually
become diverse as well.
So I have a couple of questions for you, Dr Flores. I think you
would agree that the appropriate operation in the setting of MPM
is the one most likely to result in an MCR. In many cases this deter-
mination is made at thoracotomy, and appropriately, early disease is
commonly resected by P/D when it appears that an MCR can be
achieved. As you pointed out in your study, 15% of the patients re-
ceiving P/D had stage I compared with only 3% of the patients re-
ceiving EPP. Bulky disease, which has been identified by Harvey
Pass as an indicator of poor prognosis, is more likely to be ap-
proached by EPP in terms of obtaining an MCR, and it remains un-
clear whether the type of surgical resection can actually affect the
prognosis when bulk disease has driven metastatic deposits, as
you have also shown here. Could these appropriate clinical differ-
ences in terms of bulk and cell type account for the survival differ-
ence you observed in the 2 procedures?
Dr Flores. Absolutely. I don’t think that these 2 procedures are
interchangeable. You don’t know what procedure you are going to
do until you get in there at the time of thoracotomy. That is why any
comparison that says the outcome is the same, why not just do a P/D
because you are sparing the lung? The point is if you have experi-
ence in mesothelioma surgery, you realize you can’t get most of
them out without doing an EPP. It is an intraoperative decision.
That is why there were so few EPP procedures in the patients with
stage I, because you just can’t compare it. It depends more on the
T stage. There are some pleurectomies in the stage III disease, and
those are usually patients who had N2 disease. If you have big bulky
tumor, you need an EPP, period.
Dr Sugarbaker. Given the prognostic importance of N2 that we
have demonstrated at the Brigham and your group at Memorial has
also demonstrated, at the Brigham now we are routinely performing
mediastinoscopy on patients presenting withMPM. Could you com-
ment on whether you have used this and on what you believe is the
most effective adjuvant therapy? Because MCR by either procedure
is the surgeon’s goal, how do we complete the therapy? What are
your current thoughts about what the best adjuvant treatment is?
Dr Flores. That is a point of controversy as well, what is the best
type of adjuvant therapy, and that definitely depends on the type of
procedure that you perform. If you perform an EPP and you remove
all gross disease, you don’t have the lung in place, so you can the-
oretically really crank up the radiation. At our institution we go
up to 5400 rads to really cook that chest to get the residual macro-
scopic disease. Now, those are the best results that we have obtained
in achieving local control.
For P/D, some have tried intraoperative radiotherapy, others
have tried intrapleural chemotherapy. The type of resection that
you perform dictates your adjuvant therapy.
DrM. Krasna (Towson, Md). Your group, and ours, took part in
a prospective trial using trimodality therapy for treating patients
with mesothelioma. I understand the comparison if surgery alone
was all that we are advocating. However, there are now good data
that the combination of at least adjuvant and perhaps neoadjuvant
therapy, including, for instance, chemotherapy with pemetrexed
(Alimta, Eli Lilly and Co, Indianapolis, Ind) and/or cisplatinum,
might actually have a better result both in terms of survival and com-
plete resection. Would you comment on specifically the question of
an extrapleural versus a decortication in the context of patients who
receive neoadjuvant therapy?
Dr Flores. I think as far as multimodality therapy is concerned,
when you look at these patients in this study and you compare those
who had multimodality therapy versus those who did not, there is
a survival benefit for those who had multimodality therapy. Of
course, that is a very biased group, because the patients who went
on to receive adjuvant therapy had better performance status.
When you consider the patients who had induction therapy, and
we had a phase II trial that showed that, and DrWeder from Switzer-
land also had a trial that showed that, the preliminary results are en-
couraging: a 23-month median survival in patients who underwent
resection, even a 38-month median survival. We have looked at it
in the setting of EPP. No one has really looked at induction therapy
in the setting of pleurectomy. That is an area still ripe for investiga-
tion.
DrW.Weder (Zurich, Switzerland). The survival curve after the
2 procedures goes more or less in parallel after a few months of sur-
gery. The main difference in survival between the 2 procedures oc-
curs in the early weeks or months, and because the perioperative
mortality is almost the same with 3% and 7%, I would like to
know how you explain this. Why is the early survival between the
2 groups so different?
Dr Flores.That is an excellent question, and we looked into that.
We performed this same analysis on patients after operative mortal-
ity was excluded, and the results were the same. What I think is go-
ing on, when you look at the patients with stage IV, the median
survival of the extrapleurals is 4 months. I think that is what brings
the curve down at the beginning.
Dr R. Bueno (Boston, Mass). You showed us that lymph node
status has a major impact on survival in a large cohort of patients
with mesothelioma. Did you include the lymph node status in the
multivariate analyses and did lymph node positivity affect any of
the results?
Dr Flores. We did a multivariable analysis including lymph
node status, gender, surgeon, basically those variables, and there
was no difference.
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